دورية أكاديمية
أعرض في EDS

The value of extracorporeal photopheresis as an immunosuppression-modifying approach in solid organ transplantation: a potential solution to an unmet medical need.

التفاصيل البيبلوغرافية
العنوان: The value of extracorporeal photopheresis as an immunosuppression-modifying approach in solid organ transplantation: a potential solution to an unmet medical need.
المؤلفون: Augusto JF; Department of Nephrology-Dialysis-Transplantation, University Hospital of Angers, Angers, France., Benden C; Faculty of Medicine, University of Zurich, Zurich, Switzerland., Diekmann F; Renal Transplantation Unit, Department of Nephrology and Kidney Transplantation, Hospital Clinic, Barcelona, Spain., Zuckermann A; Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.
المصدر: Frontiers in immunology [Front Immunol] 2024 May 23; Vol. 15, pp. 1371554. Date of Electronic Publication: 2024 May 23 (Print Publication: 2024).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مواضيع طبية MeSH: Photopheresis*/methods , Organ Transplantation*/adverse effects , Organ Transplantation*/methods , Graft Rejection*/prevention & control , Graft Rejection*/immunology , Immunosuppression Therapy*/methods, Humans ; Immunosuppressive Agents/therapeutic use ; Immunosuppressive Agents/adverse effects ; Graft Survival
مستخلص: Allograft rejection is a critical issue following solid organ transplantation (SOT). Immunosuppressive therapies are crucial in reducing risk of rejection yet are accompanied by several significant side effects, including infection, malignancy, cardiovascular diseases, and nephrotoxicity. There is a current unmet medical need with a lack of effective minimization strategies for these side effects. Extracorporeal photopheresis (ECP) has shown potential as an immunosuppression (IS)-modifying technique in several SOT types, with improvements seen in acute and recurrent rejection, allograft survival, and associated side effects, and could fulfil this unmet need. Through a review of the available literature detailing key areas in which ECP may benefit patients, this review highlights the IS-modifying potential of ECP in the four most common SOT procedures (heart, lung, kidney, and liver transplantation) and highlights existing gaps in data. Current evidence supports the use of ECP for IS modification following SOT, however there is a need for further high-quality research, in particular randomized control trials, in this area.
Competing Interests: CB received speaker fees from Mallinckrodt Pharmaceuticals and honoraria for an advisory role from Zambon Pharma. FD received a research grant and speaker fees from Mallinckrodt Pharmaceuticals. AZ received speaker fees from Mallinckrodt Pharmaceuticals, Chiesi and Paragonix and honoraria for an advisory role from Novartis. J-FA received a research grant and speaker fees from Mallinckrodt Pharmaceuticals. The authors declare that this study received funding from Mallinckrodt Pharmaceuticals. The funder(s) had the following involvement in the study: study design, data collection and preparation of the manuscript.
(Copyright © 2024 Augusto, Benden, Diekmann and Zuckermann.)
References: Transplantation. 1995 Jul 15;60(1):45-9. (PMID: 7624941)
Eur Heart J. 2016 Jul 14;37(27):2129-2200. (PMID: 27206819)
J Eur Acad Dermatol Venereol. 2014 Jan;28 Suppl 1:1-37. (PMID: 24354653)
Transfus Apher Sci. 2014 Jun;50(3):358-62. (PMID: 24768429)
Kidney Int. 2021 Aug;100(2):391-400. (PMID: 33838162)
Transplantation. 2018 Jul;102(7):1059-1065. (PMID: 29557913)
J Clin Apher. 2007;22(4):187-94. (PMID: 17294458)
Asian J Transfus Sci. 2017 Jul-Dec;11(2):81-86. (PMID: 28970672)
Transplantation. 2012 Jan 15;93(1):1-10. (PMID: 22138818)
Respir Med Res. 2022 May;81:100913. (PMID: 35525096)
J Heart Lung Transplant. 2010 Apr;29(4):424-31. (PMID: 19853479)
Immunotherapy. 2014;6(8):927-44. (PMID: 25313571)
World J Hepatol. 2015 Jun 8;7(10):1355-68. (PMID: 26052381)
J Eur Acad Dermatol Venereol. 2021 Jan;35(1):27-49. (PMID: 32964529)
Oncotarget. 2019 May 07;10(34):3183-3197. (PMID: 31139332)
Clin Transplant. 2017 Oct;31(10):. (PMID: 28653398)
Transfus Apher Sci. 2014 Jun;50(3):330-9. (PMID: 24837416)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
J Heart Lung Transplant. 2010 Aug;29(8):914-56. (PMID: 20643330)
Transfus Apher Sci. 2017 Aug;56(4):520-524. (PMID: 28774825)
J Clin Apher. 2010;25(3):83-177. (PMID: 20568098)
Circulation. 2004 Dec 14;110(24):3734-40. (PMID: 15596559)
Cochrane Database Syst Rev. 2022 Sep 12;9:CD012854. (PMID: 36094829)
Kidney Int. 2005 Jul;68(1):1-13. (PMID: 15954891)
Sci Adv. 2020 Mar 11;6(11):eaaz1580. (PMID: 32195350)
J Heart Lung Transplant. 2023 Aug;42(8):1131-1139. (PMID: 37037751)
Proc Am Thorac Soc. 2005;2(5):449-55. (PMID: 16322599)
Transpl Int. 2007 May;20(5):397-409. (PMID: 17403143)
Am J Transplant. 2016 Sep;16(9):2532-44. (PMID: 26932352)
Transplantation. 2005 Jan 15;79(1):123-5. (PMID: 15714180)
Cold Spring Harb Perspect Med. 2013 Jun 01;3(6):. (PMID: 23732857)
Transpl Int. 2021 Nov;34(11):2415-2417. (PMID: 34358369)
J Thorac Dis. 2014 Aug;6(8):1039-53. (PMID: 25132971)
Transpl Int. 2022 Mar 23;35:10320. (PMID: 35401042)
BMC Nephrol. 2020 Jan 6;21(1):6. (PMID: 31906890)
J Heart Lung Transplant. 2023 May;42(5):e1-e141. (PMID: 37080658)
Transplantation. 2008 Dec 15;86(11):1625-7. (PMID: 19077900)
Br J Dermatol. 2006 Jan;154(1):7-20. (PMID: 16403088)
J Heart Lung Transplant. 2019 May;38(5):493-503. (PMID: 30962148)
Transplantation. 2016 Aug;100(8):1599-600. (PMID: 27306528)
Transpl Int. 2017 Sep;30(9):903-913. (PMID: 28500792)
Curr Opin Infect Dis. 2018 Dec;31(6):499-505. (PMID: 30299353)
J Am Soc Nephrol. 1998 Jan;9(1):121-7. (PMID: 9440096)
Intensive Care Med. 2019 Mar;45(3):388-390. (PMID: 30877321)
J Eur Acad Dermatol Venereol. 2024 Mar 8;:. (PMID: 38456584)
Transfus Apher Sci. 2019 Aug;58(4):515-524. (PMID: 31383541)
Front Med (Lausanne). 2018 Aug 27;5:236. (PMID: 30211164)
Transplant Proc. 2008 May;40(4):1175-8. (PMID: 18555142)
Best Pract Res Clin Gastroenterol. 2021 Oct-Dec;54-55:101762. (PMID: 34874845)
J Clin Apher. 2009;24(4):161-9. (PMID: 19536814)
J Clin Apher. 2022 Jun;37(3):197-205. (PMID: 34936110)
Clin J Am Soc Nephrol. 2009 Feb;4(2):481-508. (PMID: 19218475)
J Eur Acad Dermatol Venereol. 2024 Mar 8;:. (PMID: 38456518)
Transfus Apher Sci. 2017 Aug;56(4):515-519. (PMID: 28774829)
J Heart Lung Transplant. 2006 Mar;25(3):283-8. (PMID: 16507420)
Gastroenterology. 2008 May;134(6):1764-76. (PMID: 18471553)
Transplant Proc. 2001 Feb-Mar;33(1-2):1591-4. (PMID: 11267432)
Transfus Apher Sci. 2014 Jun;50(3):322-9. (PMID: 23978554)
N Engl J Med. 1998 Dec 10;339(24):1744-51. (PMID: 9845709)
Transplantation. 1999 Oct 15;68(7):1056-8. (PMID: 10532551)
Cells. 2023 Sep 20;12(18):. (PMID: 37759543)
J Dermatol Sci. 2006 Aug;43(2):85-94. (PMID: 16797926)
J Clin Apher. 2021 Feb;36(1):186-188. (PMID: 32838480)
J Heart Lung Transplant. 2019 Oct;38(10):1056-1066. (PMID: 31548031)
Transplantation. 2018 Sep;102(9S Suppl 1):S1-S14. (PMID: 30113932)
Transplantation. 2000 Oct 15;70(7):1098-100. (PMID: 11045649)
Pediatr Transplant. 2018 May;22(3):e13145. (PMID: 29380491)
فهرسة مساهمة: Keywords: allograft rejection; calcineurin inhibitors; extracorporeal photopheresis; immunosuppression; solid organ transplantation
المشرفين على المادة: 0 (Immunosuppressive Agents)
تواريخ الأحداث: Date Created: 20240607 Date Completed: 20240607 Latest Revision: 20240610
رمز التحديث: 20240611
مُعرف محوري في PubMed: PMC11154098
DOI: 10.3389/fimmu.2024.1371554
PMID: 38846942
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-3224
DOI:10.3389/fimmu.2024.1371554